Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy

/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN; "Biohaven") announced today that it received orphan medicinal product designation from the European Commission (EC)...

Related Keywords

United States ,Americans ,Mike Beyer ,Jennifer Porcelli ,Irfan Qureshi ,Prnewswire Biohaven Ltd ,Biohaven Therapeutics Ltd ,European Commission ,Biohaven Ltd ,Sam Brown Inc ,Exchange Commission ,Drug Administration ,Spinal Muscular Atrophy ,Drug Designation ,Fast Track ,Orphan Drug Designation ,Orphan Designation ,Chief Medical Officer ,Taldefgrobep Alfa ,Private Securities Litigation Reform Act ,Financial Condition ,Biohaven Therapeutics ,